Using PD-L1 Immunotherapy in Clinic: A Comprehensive Overview
Explore the use of PD-L1 antibodies in guiding therapy for various cancers in clinics, including approvals, treatment options, and success rates. Stay informed about the latest advancements in immunotherapy for different types of cancers.
Uploaded on | 0 Views
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Using PD Using PD- -L1 to Guide Therapy in the Clinic L1 to Guide Therapy in the Clinic
6 PD-1/PD-L1 Antibodies, 47 Approvals (as of May 26, 2019) NSCLC: pembrolizumab, nivolumab, atezolizumab, durvalumab Melanoma : nivolumab, pembrolizumab Urothelial: nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab RCC: nivolumab, pembrolizumab, avelumab HCC: nivolumab, pembrolizumab SCLC: nivolumab, atezolizumab H&N: nivolumab, pembrolizumab CRC: nivolumab Merkel : avelumab, pembrolizumab HD: nivolumab, pembrolizumab Cervical, G/GEJ, MSI-H/dMMR, PMBCL (1): pembrolizumab TNBC: atezolizumab Skin : cemiplimab Pembrolizumab (19) Nivolumab (16) Atezolizumab (6) Avelumab (3) Durvalumab (2) Cemiplimab (1)
Thank you Thank you
